# psoriasis - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 40379
- Completion tokens: 14921
- Reasoning tokens: 0
- Total tokens: 55300
- API requests reported: 3
- Elapsed seconds: 93.849
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 2/5; original repeat 4; model vendor: DeepSeek

---
# Multidimensional Interpretation of Psoriatic Lesional Skin Transcriptomic Data

## 1. Overall Biological Interpretation

This dataset (100 genes, 90 upregulated, 10 downregulated; all with FDR ≤ 0.01) captures a coherent picture of the psoriatic lesional skin transcriptome. The dominant signal is a coordinated upregulation of genes involved in **innate immune activation and IL-17/IL-36-driven inflammation**, alongside a striking induction of **epidermal differentiation and cornified envelope components** (SPRR2 family, LCE3 family, S100 proteins, SERPINB3/B4, KRT6A). The simultaneous induction of both inflammatory mediators (IL36A/G, IL19, IL20, IL26, CXCL13, S100A8/A12) and terminal differentiation markers (SPRRs, LCEs, S100A7/A7A) reflects the characteristic "regenerative maturation" program of psoriatic keratinocytes—aberrant differentiation that is accelerated yet incomplete, producing a hyperproliferative but poorly organized epidermis. Also present are antimicrobial peptide genes (DEFB4A/B, DEFB103A/B) and downregulation of a smaller set of genes including BTC (betacellulin), CYP2W1, and several long noncoding RNAs, consistent with a shift away from normal epidermal homeostasis toward an inflammatory, injury-response state.

The statistical support is exceptionally strong: all 100 genes pass FDR ≤ 0.01, with the smallest FDR at 2.63e-146 and the largest at 8.55e-61. However, this is a single-cohort differential analysis; no independent validation cohort statistic was supplied.

## 2. Core Biological Programs

### Program 1: IL-36/IL-17-Driven Innate Inflammation
- **Direction**: Upregulated
- **Supporting genes**: IL36A (log2FC=11.37), IL36G (5.68), IL36RN (3.01), IL19 (7.58), IL20 (5.67), IL26 (4.36), IRAK2 (2.08), ZC3H12A (3.85), TNIP3 (7.28)
- **Pathway**: KEGG IL-17 signaling pathway; Reactome Interleukin-20 family signaling (R-HSA-8854691)
- **Explanation**: IL36A and IL36G are among the most strongly induced genes in the dataset. They signal through IL1RL2/IL1RAP (STRING records show IL36A interacts with IL1RL2 at confidence 0.996 and IL1RAP at 0.908), and the concurrent upregulation of IL36RN (the endogenous receptor antagonist) suggests an active negative-feedback loop. IL19, IL20, and IL26 are IL-20 family cytokines with established roles in psoriatic keratinocyte hyperproliferation and immune recruitment.
- **Evidence strength**: Strong—multiple independent genes converge on the same pathway, consistent with well-established psoriasis biology. **Limitation**: Pathway membership is inferred from annotation records, not from enrichment statistics computed on this dataset.

### Program 2: Cornified Envelope Formation and Aberrant Epidermal Differentiation
- **Direction**: Upregulated
- **Supporting genes**: SPRR2A (7.31), SPRR2B (6.38), SPRR2D (5.92), SPRR2E (3.99), SPRR2F (7.22), SPRR2G (4.75), SPRR3 (7.18), LCE3A (8.30), LCE3D (5.31), PI3 (9.24), KRT6A (4.30), KLK13 (4.05), SERPINB3 (6.74), SERPINB4 (9.12)
- **Pathway**: Reactome Formation of the cornified envelope (R-HSA-6809371); GO Epidermis development (GO:0008544)
- **Explanation**: The coordinated upregulation of small proline-rich proteins (SPRR2A–G, SPRR3), late cornified envelope proteins (LCE3A, LCE3D), and protease inhibitors (SERPINB3/B4) indicates a massive induction of the terminal differentiation program. This is the molecular signature of the thickened, hyperkeratotic epidermis characteristic of psoriatic plaques.
- **Evidence strength**: Strong—12 genes map to the Reactome cornified envelope pathway per retrieved records. **Limitation**: The strong induction likely reflects both disease biology and the altered cell-type composition of lesional skin (more keratinocytes in proliferation/differentiation states).

### Program 3: Antimicrobial Peptide and S100 Alarmin Response
- **Direction**: Upregulated
- **Supporting genes**: DEFB4A (11.18), DEFB4B (11.03), DEFB103A (5.76), DEFB103B (5.75), S100A7 (7.09), S100A7A (9.83), S100A8 (7.73), S100A12 (8.33), FABP5 (3.64)
- **Pathway**: GO Antimicrobial humoral response (GO:0019730); KEGG Staphylococcus aureus infection
- **Explanation**: The massive induction of beta-defensins and S100 alarmins represents both antimicrobial defense and endogenous danger signaling. S100A8/A12 are canonical damage-associated molecular patterns that activate TLR4 and RAGE, amplifying the inflammatory cascade. STRING records link S100A7 with FABP5, S100A12, S100A7A, SERPINB3, and SERPINB4 (5 selected genes), supporting a co-regulated module.
- **Evidence strength**: Strong within this cohort. **Limitation**: These genes are also induced in other inflammatory skin conditions; specificity to psoriasis requires comparative data not supplied here.

### Program 4: Neutrophil Chemotaxis and Myeloid Recruitment
- **Direction**: Upregulated
- **Supporting genes**: CXCR2 (2.70), CXCL13 (5.89), S100A8 (7.73), S100A12 (8.33), PLA2G4D (4.61), PLA2G4E (2.47), HPSE (2.92), GPR15LG (5.52)
- **Pathway**: KEGG Cytokine-cytokine receptor interaction; GO Response to lipopolysaccharide (GO:0032496)
- **Explanation**: CXCR2 is the major neutrophil chemoattractant receptor; its upregulation alongside S100A8/A12 (which signal through TLR4) and phospholipases A2 (PLA2G4D/E, which generate pro-inflammatory lipid mediators) indicates active myeloid cell recruitment and activation. CXCL13 suggests lymphoid organization. STRING records link GNAS with HRH2, PLA2G4D, and PLA2G4E (3 selected genes), suggesting a coordinated signaling module.
- **Evidence strength**: Moderate—supported by multiple genes but the neutrophil-specific interpretation is inferred from known biology. **Limitation**: Bulk tissue RNA cannot distinguish keratinocyte versus infiltrating immune cell origin.

### Program 5: Metabolic Reprogramming and Stress Adaptation
- **Direction**: Mixed (mostly upregulated)
- **Supporting genes**: KYNU (4.42), AKR1B10 (6.27), AKR1B15 (5.23), RRM2 (2.72), CCNE1 (2.56), SLC6A14 (4.47), ABCG4 (4.75), TCN1 (8.04)
- **Pathway**: No single standardized pathway captures this; represents amino acid metabolism (KYNU), aldo-keto reductase activity, nucleotide synthesis (RRM2), and cell cycle progression (CCNE1)
- **Explanation**: The upregulation of KYNU (kynureninase, tryptophan metabolism), AKR1B10/AKR1B15 (aldehyde/ketone reduction), and RRM2/CCNE1 (DNA synthesis and G1/S transition) indicates metabolic and proliferative stress adaptation in hyperproliferative keratinocytes.
- **Evidence strength**: Moderate—multiple genes but functionally heterogeneous. **Limitation**: This program is less specific to psoriasis and may reflect general hyperproliferation.

## 3. Key Genes and Interaction Modules

### Module 1: IL-36 Axis (IL36A, IL36G, IL36RN, IL1RAP)
- **Direction**: All upregulated (IL36A log2FC=11.37, IL36G=5.68, IL36RN=3.01)
- **Role**: Central to the IL-36/IL-17 amplification loop in psoriasis
- **Interaction nature**: STRING records show IL36A interacts with IL1RL2 (0.996), IL1RAP (0.908), and IL36RN (0.789). These are **direct physical interactions** per STRING confidence scores (receptor-ligand and antagonist-receptor relationships).

### Module 2: Cornified Envelope Genes (SPRR2A-G, LCE3A/D, PI3, KRT6A)
- **Direction**: All upregulated
- **Role**: Terminal differentiation program
- **Interaction nature**: STRING edges connect SPRR2B with LCE3A, LCE3D, SPRR2D/E/F (6 selected genes) and SPRR1B with KRT6A, SPRR2A/B/D/E (8 selected genes). These are **pathway co-membership** relationships (all components of the cornified envelope), not necessarily direct physical binding.

### Module 3: S100 Alarmin Network (S100A7, S100A7A, S100A8, S100A12, FABP5)
- **Direction**: All upregulated
- **Role**: Antimicrobial defense, DAMP signaling, amplification of inflammation
- **Interaction nature**: STRING connects S100A7 with FABP5, S100A12, S100A7A, SERPINB3, SERPINB4 (5 selected genes). These are likely **co-expression/pathway co-membership** relationships; direct S100-S100 heterodimer formation is documented for S100A8/A9 but not specifically for the pairs listed here.

### Module 4: IL-20 Family Cytokines (IL19, IL20, IL26)
- **Direction**: All upregulated (IL19=7.58, IL20=5.67, IL26=4.36)
- **Role**: Keratinocyte proliferation and immune modulation
- **Interaction nature**: STRING shows IL26 interacts with IL10RB (0.999), IL20RA (0.998), IL22RA1 (0.921), IL20RB (0.897), and IL19 (0.897). Receptor-ligand interactions are **direct physical interactions**; the IL26-IL19 relationship is likely **pathway co-membership** (both IL-20 family cytokines).

### Gene 5: KYNU
- **Direction**: Upregulated (log2FC=4.42, FDR=2.00e-91)
- **Role**: Tryptophan/kynurenine metabolism; may contribute to immune regulation via aryl hydrocarbon receptor ligands
- **Interaction nature**: No strong interaction evidence in retrieved records; **pathway co-membership** with inflammatory metabolism is putative.

### Gene 6: CXCL13
- **Direction**: Upregulated (log2FC=5.89)
- **Role**: B-cell chemoattractant; suggests lymphoid neogenesis in lesional skin
- **Interaction nature**: **Indirect/putative** relationship to other immune genes in this dataset; no direct interaction records retrieved.

### Gene 7: HPSE (Heparanase)
- **Direction**: Upregulated (log2FC=2.92)
- **Role**: Extracellular matrix remodeling, release of growth factors and chemokines from heparan sulfate
- **Interaction nature**: **Indirect**—likely facilitates immune cell infiltration by remodeling the ECM, but no direct interaction with other selected genes was retrieved.

### Gene 8: DEFB4A/DEFB4B (β-defensin 2)
- **Direction**: Both strongly upregulated (11.18, 11.03)
- **Role**: Antimicrobial peptide; copy number variation associated with psoriasis susceptibility
- **Interaction nature**: STRING connects DEFB4A/B with CCR6 and DEFB103A/B (3 selected genes), likely **pathway co-membership** in antimicrobial defense.

### Gene 9: CD274 (PD-L1)
- **Direction**: Upregulated (log2FC=3.44)
- **Role**: Immune checkpoint; may represent a counter-regulatory mechanism limiting excessive T-cell activation
- **Interaction nature**: **Indirect/putative** in this context; no direct interaction records with other selected genes retrieved.

### Gene 10: WNT5A
- **Direction**: Upregulated (log2FC=2.53)
- **Role**: Non-canonical Wnt signaling; involved in keratinocyte proliferation and inflammation
- **Interaction nature**: **Indirect/putative**—no direct interaction evidence with other selected genes in retrieved records.

## 4. Validation Priorities

### Priority 1: Cell-Type Deconvolution and Composition Check
- **Classification**: Confounding or composition check
- **Why**: The massive upregulation of both immune (IL36A, S100A8/A12, CXCR2) and keratinocyte differentiation (SPRRs, LCEs) genes could reflect increased immune cell infiltration and altered keratinocyte differentiation state rather than intrinsic transcriptional changes in a single cell type.
- **Current dataset evidence**: Bulk RNA-seq shows coordinated upregulation of both programs, but cannot localize expression to specific cell types.
- **External evidence**: Single-cell RNA-seq studies of psoriasis consistently show keratinocyte-intrinsic IL-36 expression and immune-cell-derived IL-17 (published literature).
- **Next step**: Single-cell RNA-seq or spatial transcriptomics on matched lesional and non-lesional skin; or computational deconvolution (CIBERSORTx, MuSiC).
- **Conclusion status**: Supported hypothesis (that both keratinocyte and immune programs are active), not yet established for cell-type specificity.

### Priority 2: IL-36/IL-17 Axis Functional Validation
- **Classification**: Mechanistic hypothesis
- **Why**: IL36A and IL36G are the most strongly induced genes (log2FC 11.37 and 5.68), and their receptor/antagonist (IL1RAP, IL36RN) are also upregulated, indicating an active, self-regulating inflammatory circuit.
- **Current dataset evidence**: Strong differential expression of the entire IL-36 axis.
- **External evidence**: Published literature extensively documents IL-36 as a driver of psoriatic inflammation; IL-36 receptor antagonists are in clinical development.
- **Next step**: Keratinocyte culture experiments with IL-36 stimulation ± IL36RN overexpression; or topical IL-36 inhibitor in an imiquimod mouse model.
- **Conclusion status**: Established evidence for IL-36 involvement in psoriasis biology (from literature); the specific coordinated upregulation pattern in this cohort is a supported hypothesis.

### Priority 3: Cornified Envelope Program as a Disease-Activity Biomarker
- **Classification**: Biomarker
- **Why**: SPRR2/LCE3/S100A7 genes are among the most strongly induced and are keratinocyte-specific, making them potentially quantifiable in tape-strip or serum samples.
- **Current dataset evidence**: 12+ genes in this program with very strong statistics (FDR from 2.93e-85 to 1.42e-64).
- **External evidence**: LCE3B/LCE3C deletion is a known psoriasis risk factor (GWAS); SPRR and S100 genes are reported in multiple psoriasis transcriptomic studies.
- **Next step**: Validate in an independent psoriasis cohort; test correlation with PASI score; assess whether expression decreases with successful therapy.
- **Conclusion status**: Supported hypothesis for biomarker utility; requires independent cohort validation.

### Priority 4: KYNU and Tryptophan Metabolism in Psoriatic Inflammation
- **Classification**: Mechanistic hypothesis
- **Why**: KYNU is strongly upregulated (log2FC=4.42) and represents an understudied metabolic axis in psoriasis; kynurenine pathway metabolites can modulate immune responses via aryl hydrocarbon receptor.
- **Current dataset evidence**: Single strong gene; no other tryptophan pathway genes in this dataset.
- **External evidence**: Limited but emerging literature on kynurenine pathway in inflammatory skin disease; KYNU is not a well-established psoriasis gene.
- **Next step**: Targeted metabolomics for kynurenine metabolites in lesional skin; functional studies of KYNU knockdown in keratinocytes.
- **Conclusion status**: Exploratory hypothesis.

### Priority 5: CD274 (PD-L1) Upregulation as a Counter-Regulatory Mechanism
- **Classification**: Mechanistic hypothesis
- **Why**: CD274 upregulation (log2FC=3.44) in lesional skin suggests that the inflammatory environment induces immune checkpoint expression, potentially limiting tissue damage but also providing a target for combination therapy.
- **Current dataset evidence**: Single-gene support; no other checkpoint genes in this dataset.
- **External evidence**: PD-L1 expression is reported in psoriatic epidermis; anti-PD-1 therapy can trigger or exacerbate psoriasis, suggesting a protective role for PD-L1 in skin.
- **Next step**: Immunohistochemistry for PD-L1 on lesional skin; functional studies blocking PD-L1 in psoriasis models.
- **Conclusion status**: Supported hypothesis from literature; exploratory within this dataset.

## 5. Evidence Grounding

| Claim | Direct Dataset Evidence | Pathway/Ontology | Interaction/Regulatory | Disease Association | Expression/Tissue | Literature |
|---|---|---|---|---|---|---|
| IL-36/IL-17 inflammation is a core program | Yes (IL36A/G, IL19/20/26, IRAK2) | Yes (KEGG IL-17, Reactome IL-20 family) | Yes (STRING: IL36A-IL1RL2/IL1RAP/IL36RN) | Yes (established psoriasis biology) | Yes (skin expression records) | Yes (multiple PMIDs) |
| Cornified envelope program is induced | Yes (SPRRs, LCEs, PI3, KRT6A) | Yes (Reactome R-HSA-6809371; GO epidermis development) | Yes (STRING: SPRR/LCE co-membership) | Yes (LCE3 deletion GWAS risk) | Yes (keratinocyte-specific) | Yes |
| Antimicrobial/S100 alarmin response | Yes (DEFBs, S100s) | Yes (GO antimicrobial humoral response) | Partial (STRING: S100A7 module) | Yes (psoriasis susceptibility) | Yes | Yes |
| Neutrophil recruitment | Yes (CXCR2, S100A8/A12) | Yes (KEGG S. aureus infection) | No direct interaction evidence | Moderate | Yes | Yes |
| Metabolic reprogramming | Yes (KYNU, AKR1B10, RRM2) | Partial (no single pathway) | No | Limited | Yes | Limited |

**Independence assessment**: The GO/KEGG pathway annotations, STRING interactions, and literature records are not fully independent—STRING and Reactome draw on shared published experimental data, and much of the psoriasis literature derives from overlapping transcriptomic datasets. The strongest genuinely independent support comes from (1) the uploaded statistics, (2) GWAS evidence for specific genes (e.g., LCE3 deletion, IL36RN variants), and (3) functional studies of IL-36 signaling.

## 6. Limitations and Alternative Explanations

### Limitation 1: Tissue Composition Differences
The bulk tissue comparison of lesional versus normal skin conflates changes in cell-type proportions (increased immune infiltrate, altered keratinocyte differentiation state) with cell-intrinsic transcriptional changes. The massive upregulation of both immune and differentiation genes is consistent with composition shifts. **Investigation**: Single-cell RNA-seq or computational deconvolution.

### Limitation 2: No Independent Cohort Validation
All statistics come from a single cohort. External statistical validation was not performed; pathway and literature support cannot substitute for replication in an independent psoriatic skin dataset. **Investigation**: Validate top genes in a public dataset (e.g., GEO psoriasis series) with the same direction and significance thresholds.

### Limitation 3: Disease Severity and Treatment Exposure
The dataset does not specify disease severity (PASI), disease duration, or whether patients were treatment-naïve or on therapy. Treatment (especially biologics) dramatically alters the lesional transcriptome and could confound interpretation. **Investigation**: Stratify by treatment status and severity if clinical metadata are available.

### Limitation 4: Association-Versus-Causation Ambiguity
The differential expression pattern cannot distinguish driver genes from downstream consequences. For example, IL36A upregulation could be a primary driver or a response to upstream IL-17 signaling. **Investigation**: Perturbation experiments (e.g., IL-17 blockade followed by transcriptomic profiling).

### Limitation 5: Broad/Nonspecific Pathway Signals
Some programs (antimicrobial response, metabolic reprogramming) are shared with other inflammatory skin conditions (atopic dermatitis, contact dermatitis). The absence of a comparator disease group means specificity to psoriasis cannot be assessed. **Investigation**: Include atopic dermatitis or other inflammatory skin disease as a comparator cohort.

This interpretation is grounded in the strong statistical signals of the uploaded dataset, contextualized by pathway, interaction, and literature records. The core conclusion—that psoriatic lesional skin exhibits a coordinated upregulation of IL-36/IL-20 family inflammation, cornified envelope differentiation, antimicrobial peptides, and myeloid recruitment programs—is well supported by the data and consistent with established psoriasis biology, but independent cohort replication and cell-type-resolved validation remain necessary before these patterns can be considered fully established.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=5, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
